Prosecution Insights
Last updated: November 20, 2026

Lauren Quinlan Wells, USPTO Patent Examiner

Listed by the USPTO as WELLS, LAUREN QUINLAN

Tech Center 1600 • Art Units: 1622 1625 1626 1629

This examiner grants 49% of resolved cases

Analysis

WELLS, LAUREN QUINLAN is assigned to Tech Center 1600 and Art Unit 1622. The profile records 261 resolved cases, a 49.4% allowance rate, and a median of 1120 days to allowance. The 59.5% interview lift indicates that interviews were associated with a substantial improvement over the stated baseline.

Bristol-Myers Squibb Company, INCYTE Corporation, and Genentech Inc. are the leading companies. The leading firms are BALLARD SPAHR LLP, FENWICK & WEST LLP, and FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER. The mixed allowance result and strong interview signal support building direct examiner engagement into prosecution planning, while maintaining detailed written support for claim amendments.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

49.4%
Allow Rate
-10.6% vs TC avg
354
Total Applications
+59.5%
Interview Lift
1120
Avg Prosecution Days
Based on 261 resolved cases, 2023–2026

Rejection Statute Breakdown

1.2%
§101 Eligibility
15.2%
§102 Novelty
36.0%
§103 Obviousness
28.4%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18859397 SOLID FORM OF 3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3- FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHENYL)-3-METHYL-1,3,4,9- TETRAHYDRO-2H-PYRIDO[3,4-B]INDOL-2-YL)-2,2-DIFLUOROPROPAN-1-OL TARTRATE Non-Final OA Genentech, Inc.
18835859 SMALL MOLECULES CXCR4 AGONISTS, METHOD OF SYNTHESIS, AND METHOD OF USE Non-Final OA UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED
18032320 USE OF BENZODIAZEPINES TO INCREASE SENSITIVITY TO PSILOCYBIN FOLLOWING A CHRONIC SSRI REGIMEN Final Rejection Compass Pathfinder Limited
18003431 HISTONE-ACETYLATION-MODULATING AGENTS FOR THE TREATMENT AND PREVENTION OF ORGAN INJURY Final Rejection The Regents of the University of Michigan
18875584 PRODRUGS OF PAN-KRAS INHIBITORS Non-Final OA Mirati Therapeutics, Inc.
17904393 AGENTS FOR USE IN THE TREATMENT OF TISSUE DAMAGE 2 Non-Final OA UCL BUSINESS PLC
18720716 COMPOSITIONS COMPRISING UROLITHIN FOR TREATING MUSCLE DECLINE AND A KIDNEY DYSFUNCTION Non-Final OA SOCIETE DES PRODUITS NESTLE S.A.
18697655 PHARMACEUTICAL COMBINATION CONTAINING CAPSID PROTEIN INHIBITOR AND REVERSE TRANSCRIPTASE INHIBITOR Final Rejection CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
18903075 POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 Non-Final OA Vanderbilt University
18706095 USE OF APOMORPHINE AS THERAPEUTIC AGENT FOR NECROPTOSIS-RELATED DISEASES Non-Final OA INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
18630042 ACCESSING AND MODULATING THE COLOR AND VIBRANCY OF ANODICALLY COLORING ELECTROCHROMIC MOLECULES Final Rejection Georgia Tech Research Corporation
18724765 COLLAGEN CROSS-LINKER AND USES THEREOF Non-Final OA The Curators of the University of Missouri
18109406 COMPOSITIONS AND METHODS OF REDUCING SERUM CHOLESTEROL AND PCSK9 Non-Final OA CASE WESTERN RESERVE UNIVERSITY
18834032 METHOD FOR INACTIVATING VIRUSES OR BACTERIA Non-Final OA Kao Corporation
18718477 BENZOTHIAZOLE, BENZOISOXAZOLE, AND BENZODIOXOLE ANALOGS AS RXFP1 RECEPTOR AGONISTS Non-Final OA BRISTOL-MYERS SQUIBB COMPANY
18026704 DOSAGE FORMS FOR TYK2 INHIBITORS COMPRISING SWELLABLE CORES Final Rejection Bristol-Myers Squibb Company
17928894 THERAPEUTIC DRUG FOR DISEASE CAUSED BY INTESTINAL IMMUNE DISORDER Non-Final OA KEIO UNIVERSITY
19062656 SOLID FORMS COMPRISING (S)-7-(1-ACRYLOYLPIPERIDIN-4-YL)-2-(4-PHENOXYPHENYL)-4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRIMIDINE-3-CARBOXAMIDE, AND OXALIC ACID, COMPOSITIONS AND METHODS OF USE THEREOF Non-Final OA BeiGene Switzerland GmbH
18973200 RUXOLITINIB FOR THE TREATMENT OF PRURIGO NODULARIS Non-Final OA INCYTE CORPORATION
18500214 RUXOLITINIB FOR THE TREATMENT OF PRURIGO NODULARIS Final Rejection INCYTE CORPORATION
18879103 INSECTICIDE FORMULATIONS WITH BUILT-IN ADJUVANTS Non-Final OA ADAMA MAKHTESHIM LTD.
18746787 NANOMATERIALS COMPRISING DISULFIDES Non-Final OA Beam Therapeutics Inc.
18762266 USES OF A SOMATOSTATIN MODULATOR FOR THE TREATMENT OF DISEASE Non-Final OA Crinetics Pharmaceuticals, Inc.
17798667 METHOD OF DECREASING AMYLOID BETA MONOMER LEVELS IN PATIENTS WITH COGNITIVE DECLINE Non-Final OA Cognition Therapeutics, Inc.
18088131 TOPICAL WORKOUT MUSCLE RECOVERY COMPOSITION AND ITS METHOD OF APPLICATION Non-Final OA Individual inventor

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Who Appears Before This Examiner

Top companies before this examiner

Law firms appearing most often

Frequently Asked Questions

What is examiner Lauren Quinlan Wells's allowance rate?

49.4% of resolved applications examined by Lauren Quinlan Wells were allowed (261 resolved cases), compared with 60.5% across Art Unit 1622 over the last five years.

Does an interview help with examiner Lauren Quinlan Wells?

This examiner's interview lift is +59.5 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.

How long does examiner Lauren Quinlan Wells take to allow a patent?

Applications allowed by Lauren Quinlan Wells took 1,120 days on average from filing to allowance.

Which art unit does examiner Lauren Quinlan Wells work in?

Lauren Quinlan Wells examines applications in Art Unit 1622 in Tech Center 1600 (Biotechnology & Pharmaceuticals).

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month